What is the appropriate management of hypercalcemia?

Management of Hypercalcemia

For adults with hypercalcemia of malignancy, initiate treatment with IV bisphosphonates or denosumab (with denosumab preferred), and in severe cases (calcium >14 mg/dL), add calcitonin for the first 48-72 hours only. 1

Initial Assessment and Severity Stratification

First, measure serum PTH to distinguish the underlying etiology:

• Elevated or normal PTH: Primary hyperparathyroidism (PHPT)
• Suppressed PTH (<20 pg/mL): Malignancy or other non-PTH-mediated causes 2

Classify severity by total serum calcium:

• Mild: <12 mg/dL (<3 mmol/L)
• Moderate: 12-14 mg/dL (3-3.5 mmol/L)
• Severe: >14 mg/dL (>3.5 mmol/L) 1

Management Algorithm by Etiology

Hypercalcemia of Malignancy (HCM)

Primary therapy:

• Denosumab is preferred over IV bisphosphonates for initial treatment 1
• Alternative: IV bisphosphonates (zoledronic acid or pamidronate) if denosumab unavailable 2

For severe HCM (calcium >14 mg/dL):

• Add calcitonin to denosumab or bisphosphonate for rapid calcium reduction 1
• Critical caveat: Limit calcitonin to 48-72 hours maximum due to tachyphylaxis 1

For refractory/recurrent HCM on bisphosphonates:

• Switch to denosumab 1

Supportive measures:

• IV hydration with normal saline 2, 3
• Treat the underlying malignancy (essential for long-term control) 1

Primary Hyperparathyroidism (PHPT)

Asymptomatic mild PHPT in patients >50 years:

• Observation is appropriate if calcium is <1 mg/dL above upper normal limit and no skeletal or kidney disease present 2

Symptomatic or meeting surgical criteria:

• Parathyroidectomy is curative and should be pursued 2, 3

Medical management when surgery not feasible:

• Calcimimetics for mild symptomatic cases
• IV bisphosphonates or denosumab for moderate-to-severe cases (faster onset, better tolerability) 1

Parathyroid Carcinoma

Severity-based approach:

• Mild hypercalcemia with symptoms: Start calcimimetics 1
• Moderate-to-severe hypercalcemia: Use IV bisphosphonates or denosumab as initial therapy (faster action, better tolerability) 1

Combination therapy for inadequate control:

• If calcimimetic fails: Add IV bisphosphonate or denosumab 1
• If bisphosphonate/denosumab fails: Add calcimimetic 1

Definitive treatment:

• Surgery should be considered once severe hypercalcemia is controlled 1

Other Causes

Vitamin D intoxication, granulomatous disease, lymphomas:

• Glucocorticoids are primary treatment (targets excessive intestinal calcium absorption) 2

Adrenal insufficiency:

• Glucocorticoid replacement resolves hypercalcemia 4

Lactation-associated hypercalcemia:

• Temporary cessation or tapering of breastfeeding 4

Special Populations

Kidney failure:

• Denosumab preferred over bisphosphonates
• Dialysis may be indicated 2

Key Clinical Pitfalls

1. Do not continue calcitonin beyond 72 hours - tachyphylaxis renders it ineffective and delays definitive therapy 1

2. Always measure PTH - this single test distinguishes the two most common causes (PHPT vs malignancy) accounting for 90% of cases 2, 5

3. Denosumab discontinuation can cause rebound hypercalcemia - ensure appropriate follow-up 2

4. In severe hypercalcemia, treat aggressively regardless of etiology - this is a medical emergency with significant mortality risk 3, 4

5. The 2023 Endocrine Society guidelines represent the most current evidence-based approach, though recommendations are largely conditional (grade 2) due to limited high-quality data 1